Introduction:
The late-stage pipeline of emerging therapies for the
treatment of schizophrenia continues to be dominated by atypical antipsychotics
and several depot formulations of atypical antipsychotics. Because most of
these emerging schizophrenia therapies are expected to offer only modest
advantages in safety, tolerability, and delivery over existing drugs,
significant unmet need remains in this market for more-effective medications
with minimal metabolic side effects. In the past, market opportunity for “me
too” atypical antipsychotics has been sustained by the individualized patient
response to drugs and the frequent drug-switching that takes place in this
indication. However, the increasing number of generic atypical antipsychotics
will result in a more stringent reimbursement environment, putting increasing
pressure on emerging therapies to differentiate themselves from competitors to
obtain favorable reimbursement status.
Questions Answered in This Report:
*
Reducing the global, positive, and negative symptoms are key
goals in the treatment of schizophrenia.
What are the key primary and
secondary clinical trial end points with which new therapies are evaluated? How
do U.S. and European psychiatrists weight specific efficacy end points and
other drug attributes in their prescribing decisions for schizophrenia?
*
Olanzapine (Eli Lilly’s Zyprexa) was the 2008 major-market
sales leader for schizophrenia.
Do thought leaders expect emerging therapies
to offer significant improvements in safety, tolerability, and/or delivery over
olanzapine? Which emerging therapies pose the greatest threat to olanzapine’s
status as a benchmark therapy?
*
By 2013, the paliperidone palmitate depot (Janssen’s Invega
Sustenna) will emerge as the gold-standard therapy in our Drug Comparator Model
because of its superior clinical profile over the current therapies evaluated
in this study.
On what clinical attributes is paliperidone palmitate most
differentiated from its competitors? Which current therapies are at greatest
risk of being replaced by paliperidone palmitate?Scope:
Key drug development opportunity tested in our target
product profiles for schizophrenia: an atypical antipsychotic depot
associated with a lower incidence of clinically significant weight gain than
risperidone depot at 12 weeks
Physicians surveyed for this study: 60 U.S. and 30
European psychiatrists.
Comprehensive List of Therapies Included in Our Research and Modeling
Current Therapies
- Olanzapine (Eli Lilly’s Zyprexa)
- Quetiapine (AstraZeneca’s Seroquel)
- Aripiprazole (Bristol-Myers Squibb/Otsuka Pharmaceutical’s
Abilify)
- Paliperidone (Janssen’s Invega)
- Risperidone depot (Janssen’s Risperdal Consta)
Emerging Therapies
- LY-2140023 (Eli Lilly)
- Lurasidone (Dainippon Sumitomo)
- Olanzapine pamoate (Eli Lilly’s Zyprexa Relprevv/Zypadhera)
- Paliperidone palmitate (Janssen’s Invega
Sustenna)
- Aripiprazole depot (Otsuka Pharmaceutical)